ERBB2 and neoplasm: The antagonist mentioned in their Science paper, later became the monoclonal antibody trastuzumab and when Genentech entered clinical development, an immunohistochemistry (IHC) assay that could detect HER2 protein expression levels in tumor tissue, called the clinical trial assay (CTA), was developed.